Affiliations: [a] Kuopio Research Centre of Geriatric Care, School of Pharmacy, University of Eastern Finland, Kuopio, Finland
| [b] Research Centre for Comparative Effectiveness and Patient Safety (RECEPS), University of Eastern Finland, Kuopio, Finland
| [c] Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden
| [d] Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, Kuopio, Finland
| [e]
National Institute for Health and Welfare, Helsinki, Finland
Correspondence:
[*]
Correspondence to: Dr. Pasi Lampela, School of Pharmacy, University of Eastern Finland, Kuopio Campus, PO BOX FIN-1627, 70211 Kuopio, Finland. Tel.: +358 2 94451111; Fax: +358 17 162424; E-mail: Pasi.Lampela@uef.fi.
Abstract: Background: Risk of pneumonia is increased in persons with Alzheimer’s disease (AD). In some studies, anticholinergic drugs (AC) have been associated with an increased pneumonia risk. Objective: We analyzed the risk of pneumonia associated with ACs in persons with AD. Methods: We performed a nested case-control study using register-based data from a Finnish nationwide MEDALZ cohort including all community-dwelling persons diagnosed with AD during 2005–2011. Cases were identified based on pneumonia diagnoses (n = 12,442) from hospital discharge and causes of death registers. Up to two controls without pneumonia were matched based on time since AD diagnoses, age, and gender for each case; AC use was measured using Anticholinergic Drug Scale. Results: Use of AC was associated with an increased risk of pneumonia (adjusted odds ratio (OR) 1.36, 95% confidence interval (CI) 1.29–1.43). However, there was no increased pneumonia risk in persons using level 3 ACs. Incident use was associated with higher risk of pneumonia (OR 2.68, 95% CI 2.15–3.34) than prevalent use (OR 1.48, 95% CI 1.40–1.57). Among persons using cholinesterase inhibitors (AChEIs), risk of pneumonia was increased in persons using also ACs (OR 1.53, 95% CI 1.41–1.66). Conclusion: ACs were associated with an increased risk of pneumonia in persons with AD, especially at the time of initiation of these drugs. AC use was associated with increased pneumonia risk also in persons using AChEIs. This risk should be carefully considered when treating AD patients.
